From telehealth crackdowns to home-grow legislation, these are the regulatory flashpoints shaping the continent’s cannabis future.
Europe’s cannabis landscape is shifting faster than at any point in its short legal history. While the continent still lacks a unified regulatory framework, 2026 is shaping up to be a decisive year—one in which a handful of policy battles will determine whether the European market accelerates toward maturity or stalls under regulatory uncertainty.
At Cannabis Europa London on 26–27 May, policymakers, operators, investors and clinicians will gather to debate these exact inflection points. Here are the five policy battles you need to understand before you walk through the doors.
1. The Telehealth Crackdown
Telemedicine transformed European medical cannabis access. In Germany alone, imports surged 19% in Q3 2025, driven largely by online prescribing platforms. But the backlash has arrived. Germany’s Bundesrat is moving to restrict e-prescriptions and mail-order dispensing, following Poland’s lead in tightening telehealth rules. The implications are significant: if digital prescribing is curtailed, patient access narrows, clinic economics shift, and demand risks migrating to unregulated channels. Cannabis Europa’s session on Europe’s telehealth crossroads will explore what compliance looks like in this new reality, and whether technology solutions can bridge the gap between regulation and access.
2. Hemp Ban vs Schedule 2
The legal status of hemp-derived cannabinoids remains one of Europe’s most contested regulatory questions. Semi-synthetic compounds like HHC have already been banned in at least 22 countries, while novel-food approval pathways for CBD remain inconsistent. At the same time, the debate over THC thresholds continues to divide legislators and industry alike. The question isn’t simply what’s legal—it’s what framework Europe will ultimately adopt. Will hemp sit within a consumer goods regulatory structure, or will it be pulled into pharmaceutical scheduling? This battle will be dissected on stage in London.
3. Home-Grow and Social Clubs: Stepping Stones or Dead Ends?
Germany’s Cannabis Act permits adults to grow up to three plants at home and join non-profit cannabis clubs. Luxembourg allows home cultivation of four plants but prohibits sales. The Czech Republic plans to decriminalise home growing from 2026 while keeping commercial activity illegal. These models represent genuine progress—but can they evolve into commercially viable markets, or are they regulatory cul-de-sacs designed to contain rather than enable growth? This is arguably the most consequential structural debate in European cannabis right now, and it will be front and centre at Cannabis Europa.
4. Evidence-Based Policy Design
Switzerland’s pilot programmes cap purchases at 10g THC per month and track consumption patterns. Early data shows high participant satisfaction and minimal public-order issues. The Netherlands’ regulated supply experiment includes independent research on public health, crime and nuisance. These real-world laboratories are producing the kind of data that could underpin scalable legislation—if policymakers choose to use it. The challenge lies in data collection methodology, academic partnerships and translating findings into frameworks that work across different national contexts. Expect this to be one of the most technically rich sessions of the event.
5. Driving, Working and Patient Rights
Medical cannabis patients in the UK and across Europe face daily legal ambiguity. Employment law, driving regulations and workplace drug testing policies have not kept pace with prescribing. The result is a patchwork of inconsistent rules that creates real risk for patients and employers alike. Cannabis Europa’s session on UK law and patient impact will tackle this head-on, exploring how policy needs to evolve to reflect the clinical reality of lawful cannabis use.
Why This Matters Now
These aren’t theoretical debates. Each of these five policy areas will directly impact commercial strategy, investment decisions, patient access and market structure across Europe in the next 12 to 24 months. Cannabis Europa London is where the people making these decisions will be in the room.
